Literature DB >> 21885504

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus.

Vibeke Strand, Alvina D Chu.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21885504     DOI： 10.3899/jrheum.110766

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  11 in total

Review 1.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

2.  Predictors of self-reported health-related quality of life in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Vibeke Strand; Hong Fang; Jawali Jaranilla; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

Review 3.  Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.

Authors:  Jamal Mikdashi; Ola Nived
Journal:  Arthritis Res Ther       Date:  2015-07-20       Impact factor: 5.156

Review 4.  Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance.

Authors:  Laura Holloway; Louise Humphrey; Louise Heron; Claire Pilling; Helen Kitchen; Lise Højbjerre; Martin Strandberg-Larsen; Brian Bekker Hansen
Journal:  Health Qual Life Outcomes       Date:  2014-07-22       Impact factor: 3.186

5.  Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study.

Authors:  Sophie Cleanthous; David Alan Isenberg; Stanton Peter Newman; Stefan John Cano
Journal:  Health Qual Life Outcomes       Date:  2016-03-01       Impact factor: 3.186

6.  Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.

Authors:  Vibeke Strand; Pamela Berry; Xiwu Lin; Yumi Asukai; Rajesh Punwaney; Sulabha Ramachandran
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-29       Impact factor: 4.794

7.  Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.

Authors:  Vibeke Strand; Roger A Levy; Ricard Cervera; Michelle A Petri; Helen Birch; William W Freimuth; Z John Zhong; Ann E Clarke
Journal:  Ann Rheum Dis       Date:  2013-03-22       Impact factor: 19.103

8.  Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.

Authors:  Vibeke Strand; Michelle Petri; Kenneth Kalunian; Caroline Gordon; Daniel J Wallace; Kathryn Hobbs; Lexy Kelley; Brian Kilgallen; William A Wegener; David M Goldenberg
Journal:  Rheumatology (Oxford)       Date:  2013-11-22       Impact factor: 7.580

9.  Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Authors:  Daniel J Wallace; Kenneth Kalunian; Michelle A Petri; Vibeke Strand; Frederic A Houssiau; Marilyn Pike; Brian Kilgallen; Sabine Bongardt; Anna Barry; Lexy Kelley; Caroline Gordon
Journal:  Ann Rheum Dis       Date:  2013-01-12       Impact factor: 19.103

10.  The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey.

Authors:  Caroline Gordon; David Isenberg; Kirsten Lerstrøm; Yvonne Norton; Enkeleida Nikaï; Daphnee S Pushparajah; Matthias Schneider
Journal:  Rheumatology (Oxford)       Date:  2013-09-18       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.